-The decision by the European Commission is based on data from the L-MIND study evaluating tafasitamab in combination with lenalidomide as a treatment for patients with relapsed or refractory DLBCL - Minjuvi is a new therapeutic option for eligible DLBCL patients in the European Union (EU), addressing an urgent unmet medical need - In Europe, each year approximately 16,000 patients are diagnosed with relapsed or refractory DLBCL 1,2,3 PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE /...